News

Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

CEPH International Replies to FDA Warning Letter

CEPH International Replies to FDA Warning Letter

Patheon Inc. (Mississauga, ON, Canada) announced this morning that its CEPH International subsidiary has filed a response to the US Food and Drug Administration’s Sept. 16 warning letter (see last week’s ePT).

After receiving the warning, CEPH suspended production of the oral suspension versions of the “Omnicef” powder products. The company reports that “CEPH, with the assistance of experts from Patheon, its client, and external consultants, worked diligently to analyze the issues raised by the FDA and to develop an enhanced process-improvement program to address the FDA's concerns. CEPH is currently implementing process improvements consistent with the program outlined in the response letter to the FDA.”

The company said that it anticipates resuming normal production in the first quarter of 2006, though the actual timing depends on the FDA’s response.

–Douglas McCormick

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content